Healthcare / Pharmaceutical RetailersJakartaID
$312.00
+12.00 (+4.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-105.8B · quality 67.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$550.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
16.0%
↑Gross Margin
10.6%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+18.2%
FCF CAGR
—
FCF margin
-3.7%
FCF / Net income
-2.38x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.55T · net income $55.33B · FCF $-131.51B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3547.99B | $3547.99B | $3012.74B | $2484.68B | $2147.33B |
| Net Income | $55.33B | $55.33B | $48.01B | $36.17B | $23.55B |
| EPS | 31.34 | 31.34 | 27.19 | 20.49 | 13.34 |
| Gross Margin | 10.6% | 10.6% | 11.6% | 12.2% | 10.7% |
| Operating Margin | 2.5% | 2.5% | 2.2% | 2.0% | 1.6% |
| Net Margin | 1.6% | 1.6% | 1.6% | 1.5% | 1.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 1.33 | 1.33 | 1.33 | 1.37 | 1.28 |
| Cash Flow | |||||
| Free Cash Flow | $-131.51B | $-131.51B | $-105.76B | $-69.52B | $-27.67B |
| Returns | |||||
| ROE | 16.0% | 16.0% | 16.7% | 15.6% | 16.0% |
| Growth & Yield | |||||
| Revenue Growth | 17.8% | 17.8% | 21.3% | 15.7% | — |
| EPS Growth | 15.2% | 15.2% | 32.7% | 53.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-4.0%
EPS terminal req.
$27.68
Spread vs growth
19.3%
5Y implied EPS CAGR
1.3%
EPS terminal req.
$33.50
Spread vs growth
13.9%
10Y implied EPS CAGR
5.6%
EPS terminal req.
$53.95
Spread vs growth
9.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.9%
Start / end P/E
12.9x → 10.0x
EPS bridge
27.19 → 31.34
Residual
-3.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.